This finding underscores the importance of eEF2K as a molecular target in pancreatic cancer, as its inhibition may positively influence the efficacy of gemcitabine, the first-line standard chemotherapy regimen. The gene discussed is EEF2K; the disease is familial pancreatic carcinoma.